Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) rose 46.7% on Saturday . The company traded as high as C$0.11 and last traded at C$0.11. Approximately 1,473,342 shares changed hands during mid-day trading, an increase of 283% from the average daily volume of 384,669 shares. The stock had previously closed at C$0.08.
Hemostemix Stock Performance
The company has a quick ratio of 0.48, a current ratio of 0.04 and a debt-to-equity ratio of -55.07. The business has a 50 day simple moving average of C$0.11 and a two-hundred day simple moving average of C$0.12. The firm has a market cap of C$19.58 million, a PE ratio of -2.97 and a beta of 1.39.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Recommended Stories
- Five stocks we like better than Hemostemix
- The 3 Best Fintech Stocks to Buy Now
- Auto Tariffs Are Coming Down: 3 Stocks to Benefit Soon
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Tencent Music Stock Outshines Spotify as China’s Music Giant
- There Are Different Types of Stock To Invest In
- DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy?
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
